Birchview Capital, LP Q3 2022 vs. Q4 2022: An Overview of Their 13F Holdings

Birchview Capital, LP is a hedge fund that primarily invests in the healthcare sector. As a registered investment manager, Birchview Capital, LP is required to file quarterly reports of its portfolio holdings with the Securities and Exchange Commission (SEC) using Form 13F. As a result, we've assessed their latest 13F filing for Q3 2022 and compared it against their Q4 2022 holdings. In this article, we'll provide an overview of Birchview Capital, LP's investments during the period, discussing their top holdings and analyzing their portfolio changes.

Bristol-Myers Squibb Co (BMY) – Steady Position

Bristol-Myers Squibb Co stands as Birchview Capital, LP's most significant investment, with no changes in shares from Q3 to Q4 this year. Bristol-Myers Squibb Co reflects 12.6% of the fund's total portfolio, adding up to 1.45 million shares. BMY is known for its portfolio of cancer treatments and immunotherapy drugs.

Biodesix Inc. (BDSX) – Substantial Increase

This quarter, Birchview Capital, LP increased its holdings of Biodesix Inc. shares, with a 112.55% increase from Q3 to Q4 2022. The fund owns 5.04 million shares worth $11.6 million, demonstrating their confidence in the company's ability to deliver positive returns. Biodesix is a diagnostics company that specializes in developing tests for lung and breast cancer.

Neurocrine Biosciences Inc. (NBIX) – Decreased Holdings

Birchview Capital, LP slightly decreased its holdings in Neurocrine Biosciences Inc., with just the 1.17% decrease in shares from Q3 to Q4 of 2022. The fund maintains 84,240 stocks, worth $10.06 million, in the company responsible for developing treatments for neurological and endocrine disorders.

Prothena Corp PLC (PTA) – Consistent Increase

Birchview Capital, LP has been increasing its holdings of Prothena Corp, which is up 7.26% from Q3 to Q4 of 2022. The fund reported owning 127,195 shares worth $7.66 million. Prothena Corp is a clinical-stage biopharmaceutical company that specializes in creating treatments for neurodegenerative diseases.

Azio Biologics Inc. (AZYO) – Decreased Holdings

Birchview Capital, LP decreased its holdings in the human tissue-based medical device company Azio Biologics Inc. The fund offloaded 369,000 shares resulting in 1,515,184 shares worth $6.44 million. The decrease in holdings represents a decrease of 36.9%.

Conclusion

This report offers a brief overview of Birchview Capital, LP's Q4 2022 13F Holdings by exploring their top shares up and down movements. The healthcare-focused hedge fund reported having a total value of $413.8 million of disclosed 13F assets in 39 unique holdings, with a 6.09% increase in total value from Q3 to Q4 2022. From their holdings, Bristol-Myers Squibb stands as the top holding in Q4 while Biodesix comes second, with a substantial increase and Prothena Corp occupies third place, and Azio is the only stock which Birchview Capital, LP offloaded from its Q3 2022 portfolio.